Cronos Group Inc.
Cronos is a cannabinoid company that cultivates, processes, distributes and sells cannabis products for adult-use and medical markets. It operates in Canada and Israel and distributes branded and white-labeled products in select international markets. Cronos makes money through wholesale sales to cannabis control authorities and private-sector retailers, sales to medical users through third-party distributors and pharmacies, and sales through international distribution partners. Its brands include Spinach®, PEACE NATURALS®, LIT™ and Lord Jones®. Products include dried flower, pre-rolls, vaporizers, concentrates, tinctures and edibles. Cronos reports one consolidated segment, with production facilities in Canada and Israel and a 50% equity interest in Cronos GrowCo, a principal source of cannabis. Its principal executive offices are in Stayner, Ontario, Canada.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $CRON in the last 30 days.
See all $CRON insider activity →Cronos Group (CRON) reported Q3 2026 revenue of $63.5M, up 75% YoY, with adjusted EBITDA at $17.1M and adjusted EPS of $0.04. The company entered the Netherlands market via the CanAdelaar acquisition, repurchased $9.4M in shares, and saw Canadian retail sales rise 41% YoY, with strong market share in vape and edibles.
Cronos Group reported Q3 2026 revenue of $63.5M, up 75% YoY, driven by higher cannabis flower and extract sales. CEO Mike Gorenstein discussed expansion plans, market dynamics, and derivatives. CFO Anna Slemak highlighted record gross profit and adjusted EBITDA, noting seasonal fluctuations and international sales variability. The company has $841M in cash and equivalents, with positive cash flow from operations.
Cronos Group Inc. (CRON) filed an SEC Form 8-K — Results of Operations and Financial Condition. Cronos Group Reports 2026 Third Quarter Results Organically achieved record net revenue, gross profit, and Adjusted EBITDA while reducing share count Net revenue in Q3 2026 increased by 73% year-over-year on an organic, constant-currency basis Generated record net revenue in Cana
Over the past 7 days, AlphAI's AI scored 11 news stories mentioning CRON (Cronos Group Inc.). Coverage has skewed bullish: 9 bullish, 2 neutral, and 0 bearish.
Recent CRON coverage spans earnings, financial news and mergers & acquisitions.
Earnings beat and strong revenue growth suggest upside pressure.
Strong earnings beat suggests upside pressure on the stock.
Revenue up 75% YoY and adjusted EBITDA up 201% suggest strong top‑line momentum, though net income fell.
Record revenue and EBITDA suggest growth, but lower net income may temper enthusiasm.
Adds European production capacity; modest positive impact.
AlphAI scores every news story that mentions CRON with an AI model for sentiment and relevance, and aggregates insider trades from Cronos Group Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Cronos Group (CRON) reported Q3 2026 revenue of $63.5M, up 75% YoY, with adjusted EBITDA at $17.1M and adjusted EPS of $0.04. The company entered the Netherlands market via the CanAdelaar acquisition, repurchased $9.4M in shares, and saw Canadian retail sales rise 41% YoY, with strong market share in vape and edibles.
Cronos Group reported Q3 2026 revenue of $63.5M, up 75% YoY, driven by higher cannabis flower and extract sales. CEO Mike Gorenstein discussed expansion plans, market dynamics, and derivatives. CFO Anna Slemak highlighted record gross profit and adjusted EBITDA, noting seasonal fluctuations and international sales variability. The company has $841M in cash and equivalents, with positive cash flow from operations.
Cronos Group Inc. (CRON) filed an SEC Form 8-K — Results of Operations and Financial Condition. Cronos Group Reports 2026 Third Quarter Results Organically achieved record net revenue, gross profit, and Adjusted EBITDA while reducing share count Net revenue in Q3 2026 increased by 73% year-over-year on an organic, constant-currency basis Generated record net revenue in Cana
Cronos Group reported record Q3 2026 net revenue of $63.5M, up 75% YoY, driven by strong sales in Canada, Israel, and Germany. Gross profit rose to $32.3M, while Adjusted EBITDA reached $17.1M. Spinach® maintained top market share in Canada for vapes and edibles. The company acquired CanAdelaar, strengthening its position in Europe's cannabis market.
Aurora Cannabis rejected Curaleaf's $5 per share takeover bid, exploring alternatives. Cronos Group acquired Dutch cannabis producer CanAdelaar for €57.5M. Tilray Medical gained Portuguese approval for in-house cannabis quality testing.
Cronos Group completed the €57.5 million acquisition of CanAdelaar, a licensed Dutch cannabis grower, with potential earn-outs tied to 2026 and 2027 EBITDA. The deal includes adjustments for a €12.5 million environmental penalty and indemnities up to €22.5 million. CanAdelaar is now a subsidiary of Cronos Group.
Cronos Group Inc. (CRON) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Cronos Completes Acquisition of CanAdelaar, Europe’s Largest Adult-Use Cannabis Company Cronos acquires CanAdelaar for a base purchase price of €57.5 million plus cash earnout of 0.5x Normalized EBITDA 1 in 2026 and 2027 Establishes Cronos’ European platform with #1 market share
Zuanic and Associates initiated coverage on Cronos Group (NASDAQ:CRON) with an Overweight rating, citing its founder-led focus, Altria's 42% stake, and $1 billion in cash. The company reported Q2 2026 earnings of $0.09 per share, beating estimates, with revenue of $53 million. Cronos has a market cap of $1.19 billion and a current ratio of 16.18, with plans for industry consolidation.
Cronos Group (CRON) shares rose 17% in three months due to strong Q2 2026 results, with revenue up 58% YoY to $98.2M. The company gained market share in Canada and grew international sales 67% YoY. Gross margins improved to 54% in Q2, though sustainability is uncertain. CRON faces competition and regulatory risks, with analysts cautious about future growth.
Cronos Group Inc. (CRON) shares declined 2.73% to $3.21 on Thursday, marking the third straight day of losses, while the broader market indices rose slightly.
